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Post-translational modification (PTM) of proteins plays a role in 
regulation and control of all major cellular processes.[1] This 
phenomenon involves (generally enzymatic) covalent 
attachment of a specific moiety, e.g. a phosphate, 
carbohydrate, or lipid, to a particular amino acid side-chain of a 
target protein. This in turn alters its properties, for example 
enzymatic activity, sub-cellular localization, proteolytic stability, 
or ability to interact with other proteins. A common 
characteristic feature of PTMs is their dynamic nature, and the 
existence of enzymatic activities that reverse PTMs can allow 
regulation of cellular signaling. A number of recent reports 
have demonstrated how chemical approaches can be 
particularly powerful in unraveling the process of PTM, with 
protein lipidation providing a paradigm example.[2, 3] 
 AMPylation, the covalent attachment of adenosine 
monophosphate (AMP) to hydroxyl side-chains of proteins via 
a phosphodiester bond, is yet another class of PTMs. It was 
initially observed in the 1970s in the context of metabolic 
regulation of Escherichia coli glutamine synthetase by 
glutamine synthetase adenylyl transferase,[4] but its potential 
beyond metabolic regulation went largely unexplored for the 
next four decades. It is only very recently that the field of 
protein AMPylation has been revitalized by the discovery that 
pathogenic bacteria utilize specific effector proteins 
(AMPylators) to catalyze the transfer of AMP from adenosine 
triphosphate (ATP) to host guanosine triphosphate hydrolases 
(GTPases) and disrupt their interactions with cognate binding 
partners.[5] Host GTPases are a major target of pathogenic 
bacteria as they are involved in various defense mechanisms, 
including apoptosis, pyroptosis, phagocytosis, and phagosome 
trafficking.[6-8]. Key bacterial AMPylators characterized to date 
include VopS, a cytotoxin of Vibrio parahaemolyticus, that 
AMPylates Rho family GTPases at a conserved threonine 
residue;[9] IbpA secreted by Histophilus somni, that AMPylates 
the same target protein but modifies a tyrosine residue instead 
of a threonine;[10] and finally DrrA (also known as SidM), a 
Legionella pneumophila effector that AMPylates Rab1 
GTPases also at a tyrosine.[11]  Both VopS and IbpA mediate 
AMPylation using a so-called Fido catalytic motif (canonical 
sequence: HPFx[D/E]GN[G/K]R)[12] and target the host cell 
cytoskeleton, whilst DrrA utilizes an adenylyl transferase 
domain (canonical sequence: Gx11DxD)
[11]  and targets host 
cell protein trafficking. In 2011, the first de-AMPylating enzyme, 
or ‘protein AMPylase’, was discovered in L. pneumophila, 
confirming the importance and the dynamic nature of post-
translational AMPylation.[13,14] Apart from its role in 
pathogenicity, there is growing evidence that AMPylation may 
operate as a general intracellular signaling mechanism in 
normal cell function. Bacterial Fido domain proteins are 
involved in cell division, whilst HYPE, a human Fido motif 
protein, may regulate interactions of small GTPases with their 
binding partners.[10] Furthermore, metabolic labeling 
experiments using 32P-α-ATP show numerous radioactive 
protein bands in human cell lysates, suggesting the presence 
of additional AMPylating enzymes.[9] 
 AMPylation is rapidly emerging as a fundamental 
mechanism serving to regulate protein-protein interactions and 
cell signaling in normal cells and during the invasion of 
mammalian cells by bacteria. However, without robust tools to 
identify and manipulate both AMP transferases and their 
AMPylated protein substrates our understanding of this 
complex signaling network will remain superficial. So far the 
majority of reported and predicted AMPylators in bacteria and 
eukaryotic cells have been found via bioinformatic methods 
utilizing sequence/structure similarities to Fido and adenylyl 
transferase domains.[15] In turn, AMPylated substrate proteins 
have been identified by the combination of radioactive isotope 
labeling and targeted mass spectrometric analysis both on the 
MS and MS/MS level.[9-11, 16] Two additional developments that 
complement the above-mentioned approaches include the 
elucidation of mass spectrometric fragmentation characteristics 
of AMPylation based on the analysis of synthetic peptides 
modified at serine, threonine, and tyrosine residues,[17] and the 
generation of a polyclonal antibody specific towards threonine-
AMPylation.[18] 
 In a very recent report, a potentially more general, 
chemistry-based methodology for labeling AMP transferase 
substrates has been proposed by Hang, Orth and co-
workers.[19] Specifically, the authors took advantage of the 
chemical proteomic approach that has previously been applied 
for mapping the substrates of other PTMs, such as 
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glycosylation, prenylation, and acylation, among others.[20] The 
process relies on the enzymatic transfer of a chemical handle, 
a so-called bioorthogonal reporter (usually an azide or an 
alkyne), from a synthetic substrate analogue onto the target 
protein. This biotransformation is followed by a non-enzymatic 
but highly chemoselective reaction, in this case a Cu(I)-
catalyzed azide-alkyne cycloaddition (CuAAC), with an 
appropriate ligation partner in order to introduce secondary 
labels (affinity tag or fluorophore) that allows target enrichment 
and/or detection.  It is important to emphasize that this overall 
process of chemo-enzymatic labeling introduces a covalent 
linkage between chemical tag and the modified proteins, 
allowing far more stringent washing following pull-down than 
permitted by immunoprecipitation. In their work Orth and 
Hang[19] have utilized an ATP analogue (AMP donor) that has 
been equipped by means of organic synthesis with the alkynyl 
tag at the N6 position of adenine ring (N6pATP), a site selected 
based on the structural data available for a selection of active 
Fido domains, like IbpA,[21] VopS,[22] and BepA, a Bartonella 
henselae effector.[23] The presence of the alkynyl moiety in the 
ATP analogue enables subsequent CuAAC of tagged 
AMPylated substrates with azide-bearing capture reagents 
(Figure 1).  
 
Figure 1. Chemo-enzymatic AMPylation of proteins with N
6
pATP. 
 Following the synthesis of N6pATP using a combination 
of published routes, the authors proceeded to validate the 
substrate activity and selectivity of the probe. It was 
demonstrated in the course of in vitro studies on purified 
recombinant proteins that the probe was transferred in a 
concentration-dependent manner by both Fido family (VopS 
and IbpA) and adenylyl transferase domain (DrrA) AMPylators 
onto their cognate mammalian targets, as assessed via 
CuAAC with azide-rhodamine and in-gel fluorescence. 
Furthermore, the probe was shown to be specific for its 
purpose as demonstrated by competitive inhibition with ATP as 
well as by the lack of probe transfer upon the application of 
catalytically inactive transferase mutants and transferase 
substrates in which the target threonine or tyrosine has been 
replaced by alanine. The performance of N6pATP was also 
verified against a background of mammalian cell lysate. In 
accordance with previous reports,[9-11] in-gel fluorescence 
analysis of HeLa lysates treated with the probe and the above-
mentioned recombinant AMP transferases revealed labeling of 
a distinct band in the molecular weight range of small 
GTPases. Finally, in a preliminary experiment the authors 
applied their probe to mass spectrometry-based identification 
of an AMPylated substrate within a complex protein mixture. 
HeLa lysates were incubated with a high concentration of 
N6pATP (100 M) in the presence and absence of recombinant 
VopS (~8% w/w relative to lysate proteins), followed by CuAAC 
ligation to an azidobiotin reagent that should permit affinity-
based enrichment of potential chemo-enzymatically tagged 
AMPylated substrates, and their subsequent identification by 
tandem mass spectrometry after on-bead tryptic digest. The 
proteomic analysis demonstrated the presence of the expected 
AMPylated target (Cdc42) following enrichment, albeit at 
relatively low spectral count. On the other hand, VopS itself 
was readily detected, as a result of its high concentration and 
apparent auto-AMPylation. This preliminary experiment is 
interesting, but the results remain somewhat tentative at 
present; VopS was present at a much higher concentration 
than in would be the case in vivo, a single analysis was 
performed without reconfirmation by anti-Cdc42 Western blot, 
and the full list of proteins identified +/- VopS was not 
disclosed. The probe shows great promise for de novo 
identification of novel substrates, but further experiments are 
required to confirm these observations. 
N6pATP is thus a potentially robust tool for labeling, and 
potentially also identification, of known and novel protein 
substrates of both classes of known AMP transferases. 
Importantly, it can label a variety of targets allowing the 
identification of AMPylation on all three hydroxylated amino 
acid side-chains: threonine, tyrosine, and serine. The approach 
complements immunoprecipitation and brute force MS/MS 
techniques by offering greater flexibility thanks to provision of a 
versatile handle for further manipulation. As previously seen 
for lipid modifications, dye visualization or biotin-based 
enrichment of AMPylated proteins can offer far superior 
sensitivity and robustness compared to both traditional 
radiolabeling and PTM-sensitive antibodies, respectively. 
N6pATP itself is perhaps not ideal for in vivo applications due 
to its highly charged triphosphate moiety; however, a second 
generation of substrate probes optimised for bioavailability 
may also allow the identification of AMPylated proteins in living 
systems. This would enable dynamic pulse-chase experiments 
and direct fluorescence microscopy detection of effector-
mediated AMPylation in its native environment, i.e. during 
infection of mammalian cells. Further probe modification may 
permit activity-based protein profiling (ABPP),[24, 25] a 
complementary technique that could correlate AMPylated 
proteins with the activities of known AMP transferases, and 
provide new insights into the activity of as yet undiscovered 
enzymes in this class.  
Intriguingly, very recent work has shown that the Fido 
domain-containing Legionella protein AnkX actually transfers 
phosphocholine from CDP-choline (to Rab1 and Rab35), 
rather than AMP from ATP[26] suggesting that the substrate 
tolerance of the canonical Fido motif is broader than previously 
suspected. More generally, a rich variety of novel and 
chemically diverse PTMs undoubtedly remain to be discovered 
at the host-pathogen interface that may play key roles in 
pathogenesis. PTM is an inherently chemical phenomenon, 
and the work described here furthers the role of chemical 
proteomics as a central technology in this rapidly evolving field. 
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